Browse the research platforms

Joint LYSA / LYSARC research platforms

The LYSA independent clinical research network and its operational structure LYSARC have implemented joint, very specialised research platforms that are essential to clinical and ancillary lymphoma studies

  • LYSA-IM imaging platform: Network review of imaging examinations
  • LYSA-P pathology platform: Centralised review of tumour samples
  • LYSA-BIO biology platform: Pre-analytical management of biological samples

LYSA-IM imaging platform

The LYSA-IM platform is dedicated to the networked review of imaging examinations in clinical lymphoma research projects. It is based on nuclear medicine doctors, radiologist experts in lymphomas and a LYSARC specialised technical team.

  • Nearly 5,000 images reviewed/year: positron-emission tomography (PET), tomodensitometry (TDM), Magnetic Resonance Imaging (MRI)
  • More than 10,000 examinations in the proprietary database
  • Review in less than 48 hours of the examinations that are essential for protocol treatments (responses in the course of the treatment for example)
  • Capacity for autonomous research programs and ancillary studies (ex. measure of the metabolic tumour volume)
  • Independent review committee
  • International collaborations: Italy (FIL), USA (MSKCC), Denmark (Copenhagen), the Netherlands (VU University), UK (Saint Thomas Hospital), Australia (Concord Hospital)
  • Centralised, FDA-approved web exchange platform for imaging reviews: Imagys® software (collaboration with the French company Keosys)

Site: Henri Mondor teaching hospital at Créteil (France)

LYSA-P digital pathology platform

The LYSA-P platform is dedicated to the centralised review of tissue samples taken from lymphoma patients. It is based on expert blood disease doctors of the international cooperating group LYSA and a specialised technical team of the operational structure LYSARC.

  • More than 20,000 cases reviewed so far 
  • A large collection of clinically annotated tumours: slides (classic, digitalised), paraffin blocks, frozen samples, TMA, DNA/RNA)
  • Automated high throughput analysis on large patient cohorts
  • Capacity for histopathology, digital pathology, morphometric research
  • State-of-the-art technological equipment, for digitalisation, analysis and sharing microscopic slides

Site: Henri Mondor teaching hospital at Créteil (France)

LYSA-BIO biology platform

The LYSA-BIO biology platform is dedicated to the pre-analytical management of the biological samples in clinical lymphoma studies. It includes various experts and has the logistical and technical support of dedicated LYSARC staff.

  • Collection, marking, management of samples (plasma, DNA/RNA, fresh blood, fresh cells) in a controlled environment.
  • Personalised blood analyses
  • Specific genetic analyses
  • Capacity for studying residual disease, immunomonitoring

Sites: Lyon-Sud, Rennes and Créteil